ADL BIONATUR SOLUTIONS

Trading sesion


07/12/2018 Close

1.7000

Last price


66.96 mill. €

Capitalisation

0.00

Dif.(%)


-42.95

% Year 2018

Last Trade

Date

07/12/2018

Last

1.7000

Ref.

1.7000

Dif.(%)

0.00

Volume (Shares)

1

Turnover (€x1000)

0.00

Security

Security name

ADL BIONATUR SOLUTIONS

Ticker

ADL

ISIN

ES0184980003

NIF

A-11811163

Shares Admitted

39.389.067

Nominal

0,05 Euros

Capital Admitted

1.969.453,35 Euros

Trading

Continuo

Liquidity Provider

AURIGA GLOBAL INVESTORS S.V., S.A.

Registered Advisor

IMPULSA CAPITAL S.L.

Auditor

ERNST & YOUNG S.L.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@adlbionatur.com

Historical Summary

 20142015201620172018 until 7/12

Capital Admitted (thousands of euros)

2322322552551,969

Shares (x 1,000)

4,6334,6335,0905,09039,389

Period Close Price (euros)

7.90003.60003.11002.98001.7000

Period Last Price (euros)

7.90003.60003.11002.98001.7400

Period High Price (euros)

13.98008.20005.23003.96003.6800

Period Low Price (euros)

3.53003.59002.65001.40001.6100

Capitalisation (thousands of euros)

36,60116,67915,83015,16966,961

Volume (thousands of shares)

3,3952,1364269752,653

Turnover (thousands of euros)

24,84911,9571,6082,4796,132

Company Profile

Bionaturis is a biotechnology-based group offering premium solutions for human and animal health applications. The Biotech Group comprises 4 companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific LTD) and 2 subsidiaries (BNT China Biosciences and Biobide USA) located in three different continents, being worldwide references in their markets.

The matrix company of the Group, Bionaturis -Jerez de la Frontera, Cadiz-, is devoted to Animal Health, where is positioned as a partner of choice to bring high profitable products and services to the market place. By a B2B business model Bionaturis co-develops best-in-class prescription and non-prescription products for food production animals (FPAs) and pets. Cutting-edge antigens, probiotics and feed additives, among others, are part of the broad portfolio of products to meet the main needs of a steady growing sector.

Biobide -San Sebastian- is a preclinical CRO (Contract Research Organization) worldwide leader in the use of zebrafish as animal model for efficacy and toxicity assays for the Pharma, cosmetic, nutraceutical, agri-food, and environmental sectors.

ZIP Solutions –Barcelona- is a leading company in bioprocess having a relevant portfolio of international patents around its two main assets: Splittera and Zera Vaccines (subunit 2.0 and DNA vaccines). Its business model is based on the license of its proprietary systems to tier 1 companies in the sector.

Relevant Facts and Notices

Significant participations

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.